CLCGY:OTO-Clicks Group Ltd ADR (Sponsored) (USD)

COMMON STOCK | Pharmaceutical Retailers | OTC Pink

Last Closing

USD 33.91

Change

0.00 (0.00)%

Market Cap

USD 2.38B

Volume

233.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Clicks Group Ltd is engaged in retail sale and supply of healthcare and beauty products in southern Africa. It offers health, beauty and lifestyle products to women in the middle to upper income markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-16 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
ALBHF Alibaba Health Information Tec..

N/A

USD 7.22B
RADLY Raia Drogasil SA ADR

N/A

USD 6.95B
SAEYY Shop Apotheke Europe N.V

+0.86 (+7.60%)

USD 2.48B
SHPPF Shop Apotheke Europe N.V

N/A

USD 2.28B
ZRSEF Zur Rose Group AG

N/A

USD 1.12B
NVACF Nova Cannabis Inc

-0.03 (-2.85%)

USD 0.05B
NOTR Nowtransit Inc

N/A

USD 0.04B
RADCQ Rite Aid Corporation

+0.02 (+113.33%)

USD 0.01B
RXMD Progressive Care Inc

+0.12 (+7.62%)

USD 8.74M
HEWA Healthwarehouse.Com

N/A

USD 6.97M

ETFs Containing CLCGY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.34% 60% D- 46% F
Dividend Return 1.49% 100% F 30% F
Total Return -2.85% 60% D- 45% F
Trailing 12 Months  
Capital Gain 11.55% 75% C 70% C-
Dividend Return 2.38% 100% F 33% F
Total Return 13.93% 81% B- 70% C-
Trailing 5 Years  
Capital Gain 16.93% 93% A 71% C-
Dividend Return 9.88% 100% F 33% F
Total Return 26.81% 93% A 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 2.42% 44% F 44% F
Dividend Return 4.26% 44% F 43% F
Total Return 1.84% 100% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 22.10% 96% N/A 83% B
Risk Adjusted Return 19.28% 60% D- 54% F
Market Capitalization 2.38B 92% A 81% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector